Alicia Gomez-Lopez

List of Publications by Year
in descending order

73 papers	3,593 citations	94433 37 h-index	138484 58 g-index
80 all docs	80 docs citations	80 times ranked	3344 citing authors

#	Article	IF	Citations
1	Head-to-Head Comparison of the Activities of Currently Available Antifungal Agents against 3,378 Spanish Clinical Isolates of Yeasts and Filamentous Fungi. Antimicrobial Agents and Chemotherapy, 2006, 50, 917-921.	3.2	279
2	Reclassification of the Candida haemulonii Complex as Candida haemulonii (C. haemulonii Group I), C. duobushaemulonii sp. nov. (C. haemulonii Group II), and C. haemulonii var. vulnera var. nov.: Three Multiresistant Human Pathogenic Yeasts. Journal of Clinical Microbiology, 2012, 50, 3641-3651.	3.9	201
3	Susceptibility Patterns and Molecular Identification of Trichosporon Species. Antimicrobial Agents and Chemotherapy, 2005, 49, 4026-4034.	3.2	173
4	Comparison of the Vitek 2 Antifungal Susceptibility System with the Clinical and Laboratory Standards Institute (CLSI) and European Committee on Antimicrobial Susceptibility Testing (EUCAST) Broth Microdilution Reference Methods and with the Sensititre YeastOne and Etest Techniques for In Vitro Detection of Antifungal Resistance in Yeast Isolates. Journal of Clinical Microbiology, 2010, 48, 1782-1786.	3.9	147
5	Echinocandin Susceptibility Testing ofCandidaSpecies: Comparison of EUCAST EDef 7.1, CLSI M27-A3, Etest, Disk Diffusion, and Agar Dilution Methods with RPMI and IsoSensitest Media. Antimicrobial Agents and Chemotherapy, 2010, 54, 426-439.	3.2	144
6	Prevalence and Susceptibility Profile of Candida metapsilosis and Candida orthopsilosis : Results from Population-Based Surveillance of Candidemia in Spain. Antimicrobial Agents and Chemotherapy, 2008, 52, 1506-1509.	3.2	126
7	Candida tropicalis Antifungal Cross-Resistance Is Related to Different Azole Target (Erg11p) Modifications. Antimicrobial Agents and Chemotherapy, 2013, 57, 4769-4781.	3.2	96
8	Susceptibility profile of 29 clinical isolates of Rhodotorula spp. and literature review. Journal of Antimicrobial Chemotherapy, 2005, 55, 312-316.	3.0	93
9	Value of Serial Quantification of Fungal DNA by a Real-Time PCR-Based Technique for Early Diagnosis of Invasive Aspergillosis in Patients with Febrile Neutropenia. Journal of Clinical Microbiology, 2009, 47, 379-384.	3.9	89
10	Scopulariopsis brevicaulis , a Fungal Pathogen Resistant to Broad-Spectrum Antifungal Agents. Antimicrobial Agents and Chemotherapy, 2003, 47, 2339-2341.	3.2	83
11	Comparative evaluation of two different methods of inoculum preparation for antifungal susceptibility testing of filamentous fungi. Journal of Antimicrobial Chemotherapy, 2002, 50, 719-722.	3.0	82
12	In Vitro Activities of Three Licensed Antifungal Agents against Spanish Clinical Isolates of Aspergillus spp. Antimicrobial Agents and Chemotherapy, 2003, 47, 3085-3088.	3.2	78
13	In Vitro Activities of 35 Double Combinations of Antifungal Agents against Scedosporium apiospermum and Scedosporium prolificans. Antimicrobial Agents and Chemotherapy, 2008, 52, 1136-1139.	3.2	72
14	Identification of Pathogenic Rare Yeast Species in Clinical Samples: Comparison between Phenotypical and Molecular Methods. Journal of Clinical Microbiology, 2010, 48, 1895-1899.	3.9	70
15	Combined Activity In Vitro of Caspofungin, Amphotericin B, and Azole Agents against Itraconazole-Resistant Clinical Isolates of Aspergillus fumigatus. Antimicrobial Agents and Chemotherapy, 2005, 49, 1232-1235.	3.2	65
16	In Vitro Activities of 10 Combinations of Antifungal Agents against the Multiresistant Pathogen Scopulariopsis brevicaulis. Antimicrobial Agents and Chemotherapy, 2006, 50, 2248-2250.	3.2	65
17	Determination of Isavuconazole Susceptibility of Aspergillus and Candida Species by the EUCAST Method. Antimicrobial Agents and Chemotherapy, 2013, 57, 5426-5431.	3.2	64
18	Update on the epidemiology and diagnosis of invasive fungal infection. International Journal of Antimicrobial Agents, 2008, 32, S143-S147.	2.5	58

#	Article	IF	Citations
19	In vitro susceptibility of Cryptococcus gattii clinical isolates. Clinical Microbiology and Infection, 2008, 14, 727-730.	6.0	57
20	Correlation between the procedure for antifungal susceptibility testing for Candida spp. of the European Committee on Antibiotic Susceptibility Testing (EUCAST) and four commercial techniques. Clinical Microbiology and Infection, 2005, 11, 486-492.	6.0	54
21	Development and Validation of a Quantitative PCR Assay for Diagnosis of Scedosporiosis. Journal of Clinical Microbiology, 2008, 46, 3412-3416.	3.9	54
22	Evaluation of matrix-assisted laser desorption/ionisation time-of-flight (MALDI-TOF) mass spectrometry for identification of Candida parapsilosis, C. orthopsilosis and C. metapsilosis. European Journal of Clinical Microbiology and Infectious Diseases, 2012, 31, 67-71.	2.9	54
23	Echinocandin Susceptibility Testing of Candida spp. Using EUCAST EDef 7.1 and CLSI M27-A3 Standard Procedures: Analysis of the Influence of Bovine Serum Albumin Supplementation, Storage Time, and Drug Lots. Antimicrobial Agents and Chemotherapy, 2011, 55, 1580-1587.	3.2	53
24	Rates of antifungal resistance among Spanish clinical isolates of Cryptococcus neoformans var. neoformans. Journal of Antimicrobial Chemotherapy, 2005, 56, 1144-1147.	3.0	52
25	In vitro activity of terbinafine against medically important non-dermatophyte species of filamentous fungi. Journal of Antimicrobial Chemotherapy, 2004, 53, 1086-1089.	3.0	51
26	Susceptibility profile of clinical isolates of non-Cryptococcus neoformans/non-Cryptococcus gattii Cryptococcusspecies and literature review. Medical Mycology, 2010, 48, 90-96.	0.7	51
27	In vitro evaluation of combination of terbinafine with itraconazole or amphotericin B against Zygomycota. Diagnostic Microbiology and Infectious Disease, 2003, 45, 199-202.	1.8	49
28	In Vitro Activities of Ravuconazole and Four Other Antifungal Agents against Fluconazole-Resistant or -Susceptible Clinical Yeast Isolates. Antimicrobial Agents and Chemotherapy, 2004, 48, 3107-3111.	3.2	49
29	Utility of Real-time PCR for the detection ofParacoccidioides brasiliensisDNA in the diagnosis of imported paracoccidioidomycosis. Medical Mycology, 2009, 47, 879-882.	0.7	48
30	IdentificaciÃ³n molecular y sensibilidad a los antifÃºngicos de cepas de Trichosporon aisladas en un hospital de Brasil. Revista Iberoamericana De Micologia, 2008, 25, 221-225.	0.9	47
31	Incidence of zygomycosis in transplant recipients. Clinical Microbiology and Infection, 2009, 15, 37-40.	6.0	47
32	In Vitro Activity of Ravuconazole against 923 Clinical Isolates of Nondermatophyte Filamentous Fungi. Antimicrobial Agents and Chemotherapy, 2005, 49, 5136-5138.	3.2	46
33	Executive summary of clinical practice guideline for the management of invasive diseases caused by Aspergillus: 2018 Update by the GEMICOMED-SEIMC/REIPI. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2019, 37, 535-541.	0.5	46
34	Activity Profile In Vitro of Micafungin against Spanish Clinical Isolates of Common and Emerging Species of Yeasts and Molds. Antimicrobial Agents and Chemotherapy, 2009, 53, 2192-2195.	3.2	45
35	Analysis of the Influence of Tween Concentration, Inoculum Size, Assay Medium, and Reading Time on Susceptibility Testing of Aspergillus spp. Journal of Clinical Microbiology, 2005, 43, 1251-1255.	3.9	41
36	First detection of Aspergillus fumigatus azole-resistant strain due to Cyp51A TR46/Y121F/T289A in an azole-naive patient in Spain. New Microbes and New Infections, 2015, 6, 33-34.	1.6	40

#	Article	IF	Citations
37	Molecular identification, antifungal resistance and virulence of Cryptococcus neoformans and Cryptococcus deneoformans isolated in Seville, Spain. Mycoses, 2017, 60, 40-50.	4.0	40
38	An invertebrate model to evaluate virulence in Aspergillus fumigatus: The role of azole resistance. Medical Mycology, 2014, 52, 311-319.	0.7	38
39	In vitro susceptibility of clinical isolates of Zygomycota to amphotericin B, flucytosine, itraconazole and voriconazole. Journal of Antimicrobial Chemotherapy, 2001, 48, 919-921.	3.0	37
40	Protective effect of enriched diet plus growth hormone administration on radiation-induced intestinal injury and on its evolutionary pattern in the rat. Digestive Diseases and Sciences, 1999, 44, 2350-2358.	2.3	36
41	Genotype distribution of clinical isolates of Trichosporon asahii based on sequencing of intergenic spacer 1. Diagnostic Microbiology and Infectious Disease, 2007, 58, 435-440.	1.8	36
42	Process Analysis of Variables for Standardization of Antifungal Susceptibility Testing of Nonfermentative Yeasts. Antimicrobial Agents and Chemotherapy, 2011, 55, 1563-1570.	3.2	33
43	Posaconazole: The Case for Therapeutic Drug Monitoring. Therapeutic Drug Monitoring, 2012, 34, 72-76.	2.0	32
44	HPLC/UV or bioassay: two valid methods for posaconazole quantification in human serum samples. Clinical Microbiology and Infection, 2012, 18, 1229-1235.	6.0	32
45	Differences in Interactions between Azole Drugs Related to Modifications in the 14-Î± Sterol Demethylase Gene (cyp51A) of Aspergillus fumigatus. Antimicrobial Agents and Chemotherapy, 2005, 49, 2119-2121.	3.2	30
46	Prevalence ofCandida bracarensisandCandida nivariensisin a Spanish collection of yeasts: comparison of results from a reference centre and from a population-based surveillance study of candidemia. Medical Mycology, 2011, 49, 1-5.	0.7	28
47	Analysis of Performance of a PCR-Based Assay To Detect DNA of Aspergillus fumigatus in Whole Blood and Serum: a Comparative Study with Clinical Samples. Journal of Clinical Microbiology, 2011, 49, 3596-3599.	3.9	27
48	Recurrent Episodes of Candidemia Due to Candida glabrata with a Mutation in Hot Spot 1 of the FKS2 Gene Developed after Prolonged Therapy with Caspofungin. Antimicrobial Agents and Chemotherapy, 2012, 56, 3417-3419.	3.2	27
49	Voriconazole serum levels measured by high-performance liquid chromatography: a monocentric study in treated patients. Medical Mycology, 2012, 50, 439-445.	0.7	24
50	In vivo efficacy of voriconazole and posaconazole therapy in a novel invertebrate model of Aspergillus fumigatus infection. International Journal of Antimicrobial Agents, 2015, 46, 511-517.	2.5	24
51	Molecular identification and susceptibility profile in vitro of the emerging pathogen Candida kefyr. Diagnostic Microbiology and Infectious Disease, 2010, 66, 116-119.	1.8	22
52	Pharmacotherapy of yeast infections. Expert Opinion on Pharmacotherapy, 2008, 9, 2801-2816.	1.8	21
53	An alternative host model of a mixed fungal infection by azole susceptible and resistantAspergillusspp strains. Virulence, 2015, 6, 376-384.	4.4	21
54	Frequency of Voriconazole ResistanceIn Vitroamong Spanish Clinical Isolates ofCandidaspp. According to Breakpoints Established by the Antifungal Subcommittee of the European Committee on Antimicrobial Susceptibility Testing. Antimicrobial Agents and Chemotherapy, 2011, 55, 1794-1797.	3.2	20

#	Article	IF	Citations
55	Comparison of Dimethyl Sulfoxide and Water as Solvents for Echinocandin Susceptibility Testing by the EUCAST Methodology. Journal of Clinical Microbiology, 2012, 50, 2509-2512.	3.9	19
56	Detection of fungal DNA by real-time polymerase chain reaction: evaluation of 2 methodologies in experimental pulmonary aspergillosis. Diagnostic Microbiology and Infectious Disease, 2006, 56, 387-393.	1.8	17
57	Simultaneous quantification of systemic azoles and their major metabolites in human serum by HPLC/PDA: role of azole metabolic rate. Diagnostic Microbiology and Infectious Disease, 2018, 92, 78-83.	1.8	16
58	Pharmacokinetics of echinocandins in suspected candida peritonitis: A potential risk for resistance. International Journal of Infectious Diseases, 2020, 101, 24-28.	3.3	16
59	Development and validation of a fast HPLC/photodiode array detection method for the measurement of voriconazole in human serum samples. A reference laboratory experience. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2013, 31, 23-28.	0.5	15
60	In vitro antifungal susceptibility pattern and ergosterol content in clinical yeast strains. Revista Iberoamericana De Micologia, 2011, 28, 100-103.	0.9	9
61	A simple, sensitive HPLC-PDA method for the quantification of itraconazole and hydroxy itraconazole in human serum: a reference laboratory experience. Diagnostic Microbiology and Infectious Disease, 2013, 76, 314-320.	1.8	9
62	Determination of Voriconazole Serum Concentration by Bioassay, a Valid Method for Therapeutic Drug Monitoring for Clinical Laboratories. Antimicrobial Agents and Chemotherapy, 2013, 57, 3437-3440.	3.2	9
63	Analysis of strain relatedness using High Resolution Melting in a case of recurrent candiduria. BMC Microbiology, 2013, 13, 13.	3.3	8
64	Reliability of the WIDERYST Susceptibility Testing System for Detection of In Vitro Antifungal Resistance in Yeasts. Antimicrobial Agents and Chemotherapy, 2008, 52, 1062-1065.	3.2	6
65	Multicenter Comparison of the ISO Standard 20776-1 and the Serial 2-Fold Dilution Procedures To Dilute Hydrophilic and Hydrophobic Antifungal Agents for Susceptibility Testing. Journal of Clinical Microbiology, 2010, 48, 1918-1920.	3.9	6
66	Comparison of Caspofungin MICs by Means of EUCAST Method EDef 7.1 Using Two Different Concentrations of Glucose. Antimicrobial Agents and Chemotherapy, 2010, 54, 3056-3057.	3.2	5
67	Blood and tissue distribution of posaconazole in a rat model of invasive pulmonary aspergillosis. Diagnostic Microbiology and Infectious Disease, 2017, 87, 112-117.	1.8	5
68	Incidence of E. coli O157:H7 and other enteropathogens in a Spanish hospital. European Journal of Epidemiology, 2000, 16, 303-304.	5.7	4
69	High-Resolution Melting Assay for Genotyping Variants of the CYP2C19 Enzyme and Predicting Voriconazole Effectiveness. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	4
70	Invasive aspergillosis in a paediatric allogeneic stem cell transplantation recipient owing to a susceptible Aspergillus fumigatus: Treatment failure with high doses of voriconazole and influence of CYP2C19 polymorphisms. International Journal of Antimicrobial Agents, 2016, 47, 410-411.	2.5	2
71	Galactomannan enzyme immunoassay and quantitative Real Time PCR as tools to evaluate the exposure and response in a rat model of aspergillosis after posaconazole prophylaxis. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2016, 34, 571-576.	0.5	2
72	A new cause of false positive voriconazole levels: Watch your collection tubes!. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2018, 1092, 328-331.	2.3	0

#	Article	IF	Citations
73	A survey to describe common practices on antifungal monitoring among Spanish clinicians. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2023, 41, 18-23.	0.5	0